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To the Editor: Streptobacillus
moniliformis is a facultatively anaero-
bic, pleomorphic, gram-variable bacil-
lus often seen in chains and as long
unbranched filaments. It is found in
the nasopharynx and oropharynx of
wild and laboratory rats. Human infec-
tions result either from rodent bites
(rat bite fever) or contaminated milk
or other foods (Haverhill fever). The
most common manifestations of infec-
tion are arthralgia, fever, and rash;
endocarditis occurs as a rare complica-
tion (1). We report a case of S. monili-
formis endocarditis in India in a
patient with congenital heart disease.
An 18-year-old man was admitted
to the Department of Cardiology at
the Government General Hospital in
Chennai, India, in November 2005,
with a fever of 2 months’ duration
with cough, epistaxis, palpitations,
and persistent joint pain. His medical
history indicated congenital heart dis-
ease with a ventricular septal defect.
On physical examination, his blood
pressure was 100/70 mm Hg, pulse
rate was 100 beats/min, and tempera-
ture was 38.5°C. Laboratory tests
showed a leukocyte count of 7,600/µL,
a platelet count of 127,000/µL, and an
erythrocyte sedimentation rate of 70
mm/h. An electrocardiogram showed
normal sinus rhythm. A transthoracic
echocardiogram demonstrated a ven-
tricular septal defect and vegetations
on the septal leaflet of the tricuspid
valve.
Three blood cultures were pre-
pared, and treatment with antimicro-
bial drugs (intravenous penicillin G, 3
×  106 Uevery 6 h, and gentamicin, 50
mg every 8 h for 4 weeks) was initiat-
ed. The blood cultures were incubated
at 37°C in an atmosphere of 5%–10%
CO2. Characteristic white, downy,
crumblike granules were observed on
the surface of the erythrocytes in all 3
cultures within 18–24 h of incubation.
Characteristic puff balls were seen
after 48 h of incubation. Gram-stained
smears showed gram-negative bacilli
in long chains. Cultures were subcul-
tured onto 5% sheep blood agar plates
and MacConkey agar plates. The
plates were incubated at 37°C in an
atmosphere of 5%–10% CO2. After
18–24 h of incubation, growth was
seen on the sheep blood agar plates.
Colonies were 1–2 mm in diameter,
gray, smooth, and butyrous. A Gram
stain of these colonies identified gram-
variable, pleomorphic coccobacilli
that were negative for catalase, oxi-
dase, urease, and citrate, and did not
produce indole or reduce nitrate.
Antimicrobial susceptibility testing
was performed by using the Kirby-
Bauer disk diffusion method accord-
ing to recommendations of the
National Committee for Clinical labo-
ratory Standards (2). The isolate was
sensitive to penicillin G, ceftriaxone,
cephalexin, amoxicillin, gentamicin,
and erythromycin. The patient
responded well to treatment and
became afebrile within 48 h after initi-
ation of therapy. Treatment with
antimicrobial drugs was continued for
4 weeks. The blood cultures were neg-
ative when repeated after 2 weeks. The
patient had an uneventful recovery and
was discharged from the hospital.
Rat bite fever is a zoonosis caused
by either Streptobacillus moniliformis
or  Spirillum minus (1,3).  S. monili-
formis is found in the nasopharynx of
small rodents, especially rats. Rats
that are carriers have no symptoms
but can effectively transmit the infec-
tion by bite or through infected body
fluids such as urine. 
This patient had a history of living
in a rat-infested area, and admitted
having been bitten by a rat several
months before the onset of symptoms.
However, we considered it unlikely
that disease contracted by a rat bite
would take months to be manifested.
Thus, it is more likely that he con-
tracted the infection from food or
water contaminated with rat excreta.
Endocarditis is a rare complication of
S. moniliformis infection, and cardiac
valvular abnormalities have been
reported in 50% of cases (4). This
patient, however, had only a small
ventricular septal defect. This is the
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West Nile Virus in
Horses, Guatemala
To the Editor: West Nile virus
(WNV,  Flaviviridae: Flavivirus) is
emerging as a public health and vet-
erinary concern. Since its introduction
into North America in 1999, it has
spread rapidly, reaching the
Caribbean Basin in 2001, Mexico in
2002, El Salvador in 2003, and
Colombia in 2004 (1). However,
reports of equine illness and deaths in
Latin America are inconclusive. With
the exception of viral isolates from a
dead bird, a human, and a mosquito
pool in Mexico (2,3), all reports of
WNV presence in Latin America have
relied on serologic evidence. WNV is
a member of the Japanese encephalitis
serocomplex, which in the Western
Hemisphere includes St. Louis
encephalitis virus (SLEV) (4).
Serologic investigations for WNV in
Latin America must use highly specif-
ic assays to differentiate WNV infec-
tion from potentially cross-reactive
viruses such as SLEV or possibly
additional unknown viruses. In partic-
ular, SLEV is of concern since it was
previously isolated from Guatemalan
mosquitoes (5).
Alerted by the findings of WNV
transmission in the region (1), we col-
lected serum samples from horses
from 19 departments of Guatemala
from September 2003 to March 2004,
to initially estimate the extent of
WNV spread and its potential public
health risk. Because no animals
exhibited signs of neurologic illness
at the time of the survey, only healthy
horses were sampled. Before 2005,
equine WNV vaccines were prohibit-
ed and unavailable in Guatemala
(Unidad de Normas y Regulaciones,
Ministerio de Agricultura Ganadería y
Alimentación, Guatemala, pers.
comm.); as such, cross-reactivity due
to prior vaccination is highly unlikely.
Samples were initially tested for
WNV-reactive antibodies by using an
epitope-blocking enzyme-linked
immunosorbent assay (blocking
ELISA) (6). The ability of the test sera
to block the binding of the monoclon-
al antibodies to WNV antigen was
compared to the blocking ability of
control horse serum without antibody
to WNV. Data were expressed as rela-
tive percentages and inhibition values
>30% were considered to indicate the
presence of viral antibodies.
A subset of positive samples was
further confirmed by plaque-reduc-
tion neutralization test (7). Of 352
samples, 149 (42.3%) tested positive
with the 3.1112G WNV-specific mon-
oclonal antibody. Of 70 blocking
ELISA–positive samples, the neutral-
ization tests indicated the infecting
agent was WNV, SLEV, and undiffer-
entiated flavivirus in 9, 33, and 21
samples, respectively. Titers were
expressed as the reciprocal of serum
dilutions yielding >90% reduction in
the number of plaques in a plaque-
reduction neutralization test
(PRNT90). PRNT90 titers of horses
seropositive for WNV ranged from 80
to 320. PRNT90 titers of horses
seropositive for SLEVranged from 40
to 2,560. For the differential diagnosis
of samples with neutralizing antibody
titers against both WNV and SLEV in
this test, a >4-fold titer difference was
used to identify the etiologic agent.
The undifferentiated flavivirus-reac-
tive specimens had <4-fold difference
in cross-neutralization titers. Likely
possibilities for the inability to distin-
guish the infecting virus include pre-
vious infection with these or other fla-
viviruses (previously described or
unknown) resulting in elevated cross-
reactive titers. The remaining 10% of
specimens that tested negative by
PRNT probably represent nonneutral-
izing antibodies in the serum or false
positivity in the blocking ELISA.
Our serologic results provide indi-
rect evidence of past transmission of
WNV, SLEV, and possibly other fla-
viviruses to horses in Guatemala.
Although no confirmed cases of
WNV-attributed disease have been
reported in Central America to date,
flavivirus transmission appears to be
widely distributed in Guatemala
(Figure). Efforts are under way to
confirm WNV transmission by viral
isolation and to evaluate the impact of
WNV on human, horse, and wildlife
populations. More information is
needed to establish the public health
threat of WNV and other zoonotic fla-
viviruses in the region.
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